Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET).
AuthorsMalinovszky, K M
Dixon, J M
Leonard, R C F
AffiliationSouth West Wales Cancer Institute, Singleton Hospital, Swansea SA2 8QA, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractWomen with hormone responsive breast cancer routinely receive endocrine therapy. There is growing evidence that patients experience significant side effects. Between 1996 and 1998, all patients on endocrine therapy for adjuvant or advanced breast cancer, attending the Edinburgh Breast Unit, were invited to complete a checklist for patients on endocrine therapy. This simple form, designed as a communication aid, was completed by patients before their consultation. 708 patients (age 28-93) completed 1060 forms. These forms were analysed in order to gain a better understanding of the side effects experienced. Most patients were on tamoxifen (n = 524), with 103 on anastrazole and 35 on megestrol acetate. Common symptoms experienced were hot flushes, sweats and weight gain. Symptoms varied according to the patients' ages and the setting in which they received endocrine treatment. Pre-menopausal women were more likely to experience problems with flushes, sweats, weight gain and reduced libido.
CitationBreast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). 2004, 13 (5):363-8 Breast
- Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study.
- Authors: Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B
- Issue date: 2009
- Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
- Authors: Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A
- Issue date: 2007 Feb 10
- Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
- Authors: Duric VM, Fallowfield LJ, Saunders C, Houghton J, Coates AS, Stockler MR
- Issue date: 2005 Dec 12
- The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
- Authors: Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA
- Issue date: 2009 Aug
- Temporal trends in the use of adjuvant systemic therapy in breast cancer: a population based study in Sweden 1976-2005.
- Authors: Kemetli L, Rutqvist LE, Jonsson H, Nyström L, Lenner P, Törnberg S
- Issue date: 2009